0000000000437327

AUTHOR

Lorenzo Menicanti

showing 7 related works from this author

Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicentre Italian CORIST Study

2021

Abstract Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who receive…

Malemedicine.medical_specialtySettore MED/17 - Malattie Infettivecoronavirusheparin030204 cardiovascular system & hematologyLower risklaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineClinical endpointmedicineHumansThrombophilia030212 general & internal medicineHospital MortalityBlood CoagulationSurvival analysisAgedRetrospective Studiestreatmentbusiness.industryHeparinMortality rateCOVID-19mortalityLow-Molecular-WeightAnticoagulantsCOVID-19Retrospective cohort studyHeparinHematologyHeparin Low-Molecular-WeightMiddle AgedmortalitySurvival AnalysisCOVID-19 Drug Treatmentcoagulation activationcoronaviruItalytreatmentsPropensity score matchingcoagulation activation; coronavirus; COVID-19; heparin; mortality; treatmentsFemalecoagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophiliabusinessmedicine.drug
researchProduct

Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian…

2020

Abstract Background Hydroxychloroquine (HCQ) was proposed as potential treatment for COVID-19. Objective We set-up a multicenter Italian collaboration to investigate the relationship between HCQ therapy and COVID-19 in-hospital mortality. Methods In a retrospective observational study, 3,451 unselected patients hospitalized in 33 clinical centers in Italy, from February 19, 2020 to May 23, 2020, with laboratory-confirmed SARS-CoV-2 infection, were analyzed. The primary end-point in a time-to event analysis was in-hospital death, comparing patients who received HCQ with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatme…

Malemedicine.medical_specialty030204 cardiovascular system & hematologyLower risklaw.inventionCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality; Aged; Aged 80 and over; COVID-19; Female; Hospital Mortality; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; Treatment OutcomeCOVID-19; Disease severity; Hydroxychloroquine; Inflammation; Mortality03 medical and health sciences0302 clinical medicineRandomized controlled trialRetrospective StudielawInternal medicine80 and overInternal MedicinemedicineHumans030212 general & internal medicineHospital MortalityMortalityRisk factorDisease severityAgedRetrospective StudiesInflammationAged 80 and overbusiness.industryMortality rateCOVID-19HydroxychloroquineRetrospective cohort studyMiddle AgedCOVID-19 Drug TreatmentTreatment OutcomeItalyPropensity score matchingCommentaryObservational studyFemalebusinessHumanmedicine.drugHydroxychloroquineEuropean journal of internal medicine
researchProduct

RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis…

2020

Abstract Objective The hypothesis that been set forward that use of Renin Angiotensin Aldosterone System (RAAS) inhibitors is associated with COVID−19 severity. We set-up a multicenter Italian collaboration (CORIST Project, ClinicalTrials.gov ID: NCT04318418 ) to retrospectively investigate the relationship between RAAS inhibitors and COVID−19 in-hospital mortality. We also carried out an updated meta-analysis on the relevant studies. Methods We analyzed 4069 unselected patients with laboratory-confirmed SARS-CoV-2 infection and hospitalized in 34 clinical centers in Italy from February 19, 2020 to May 23, 2020. The primary end-point in a time-to event analysis was in-hospital death, compar…

0301 basic medicineMalePhysiologyMiddle Aged Renin-Angiotensin SystemAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyACE-I; ARB; COVID-19; angiotensin converting enzyme inhibitors; angiotensin receptor blockers; mortality; sartansSeverity of Illness IndexRenin-Angiotensin System0302 clinical medicineangiotensin converting enzyme inhibitorsRisk FactorsACE-I80 and overMedicineHospital MortalitySartanAged 80 and overIncidence (epidemiology)IncidenceHazard ratioAngiotensin Receptor AntagonistMiddle AgedsartansARBHospitalizationAntihypertensive AgentItalyMeta-analysisHypertensionSartansMolecular MedicineFemaleRisk assessmentHumanmedicine.medical_specialtyAngiotensin converting enzyme inhibitors; ACE-I; Angiotensin receptor blockers; ARB; Sartans; COVID-19; MortalityCoronavirus disease 2019 (COVID-19)Risk AssessmentArticleCOVID−1903 medical and health sciencesAngiotensin Receptor AntagonistsMeta-Analysis as TopicInternal medicineSeverity of illnessHumansAngiotensin receptor blockerMortalityAntihypertensive AgentsAgedPharmacologyACE-I; ARB; Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; COVID−19; Mortality; Sartans; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; COVID-19; Female; Hospitalization; Humans; Hypertension; Incidence; Italy; Male; Meta-Analysis as Topic; Middle Aged; Renin-Angiotensin System; Risk Assessment; Risk Factors; Severity of Illness Index; Hospital Mortalitybusiness.industryRisk FactorCOVID-19Angiotensin-Converting Enzyme InhibitorAngiotensin receptor blockersmortalityConfidence intervalangiotensin receptor blockersAngiotensin converting enzyme inhibitors030104 developmental biologyACE-I; ARB; COVID-19 angiotensin converting enzyme inhibitors angiotensin receptor blockers mortality sartansObservational studyAngiotensin converting enzyme inhibitorbusiness
researchProduct

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings f…

2020

Background and aims There is poor knowledge on characteristics, comorbidities and laboratory measures associated with risk for adverse outcomes and in-hospital mortality in European Countries. We aimed at identifying baseline characteristics predisposing COVID-19 patients to in-hospital death. Methods and results Retrospective observational study on 3894 patients with SARS-CoV-2 infection hospitalized from February 19th to May 23rd, 2020 and recruited in 30 clinical centres distributed throughout Italy. Machine learning (random forest)-based and Cox survival analysis. 61.7% of participants were men (median age 67 years), followed up for a median of 13 days. In-hospital mortality exhibited a…

MaleEpidemiologyEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologycomputer.software_genreMachine Learning0302 clinical medicineRetrospective StudieRisk FactorsCardiovascular DiseaseEpidemiology80 and overMedicineAge FactorViralHospital MortalityBetacoronavirus Hospital MortalityYoung adultAged 80 and overNutrition and DieteticsCOVID-19; Epidemiology; In-hospital mortality; Risk factorsMortality rateHazard ratioAge FactorsMiddle AgedIn-hospital mortalityC-Reactive ProteinCardiovascular DiseasesFemaleSurvival AnalysiCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentPneumonia Viral030209 endocrinology & metabolismSettore MED/17 - MALATTIE INFETTIVEMachine learningCOVID-19; Epidemiology; In-hospital mortality; Risk factors; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; C-Reactive Protein; COVID-19; Cardiovascular Diseases; Coronavirus Infections; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pandemics; Pneumonia Viral; Retrospective Studies; Risk Factors; SARS-CoV-2; Survival Analysis; Young Adult; Betacoronavirus; Hospital Mortality; Machine LearningArticle03 medical and health sciencesBetacoronavirusYoung AdultHumansRisk factorPandemicsSurvival analysisAgedRetrospective StudiesPandemicBetacoronavirubusiness.industryCoronavirus InfectionSARS-CoV-2Risk FactorCOVID-19Retrospective cohort studyPneumoniaSurvival AnalysisConfidence intervalRisk factorsArtificial intelligencebusinesscomputerNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Lopinavir/ritonavir and darunavir/cobicistat in hospitalized covid-19 patients: Findings from the multicenter italian corist study

2021

Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients.Study Design: Multicenter observational study of COVID-19 patients admitted in 33 Italian hospitals. Medications, preexisting conditions, clinical measures, and outcomes were extracted from medical records. Patients were retrospectively divided in three groups, according to use of LPV/r, DRV/c or none of them. Primary outcome in a time-to event analysis was death. We used Cox proportional-hazards models with inverse probability of…

Medicine (General)medicine.medical_specialtyLopinavir/ritonavirLopinavirR5-920Internal medicinemedicineDarunavirOriginal ResearchCOVID-19; Darunavir; In-hospital mortality; Lopinavir; SARS-CoV-2DarunavirCOVID-19; SARS-CoV-2; darunavir; in-hospital mortality; lopinavirbusiness.industrySARS-CoV-2CobicistatMortality rateCOVID-19LopinavirGeneral Medicinemedicine.diseaseIn-hospital mortalityPropensity score matchingMedicineRitonavirbusinessmedicine.drugKidney disease
researchProduct

Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering

2021

The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and experimental studies reporting contrasting results. To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February–May 2020). Patients’ characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases, and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distan…

MaleMedicine (General)Antimalarial030204 cardiovascular system & hematologySeverity of Illness IndexHospital Mortality.0302 clinical medicineRetrospective Studie80 and overCluster Analysis030212 general & internal medicineHospital MortalityAged; Aged 80 and over; Antimalarials; COVID-19; Cluster Analysis; Female; Humans; Hydroxychloroquine; Italy; Male; Middle Aged; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; Hospital MortalityAged 80 and overMiddle AgedTreatment OutcomeItalyFemaleBiotechnologymedicine.drugResearch ArticleHydroxychloroquinemedicine.medical_specialtyArticle SubjectBiomedical EngineeringRenal functionHealth Informatics03 medical and health sciencesAntimalarialsR5-920Internal medicineDiabetes mellitusSeverity of illnessmedicineMedical technologyHumansR855-855.5AgedRetrospective StudiesCluster Analysibusiness.industrySARS-CoV-2CancerCOVID-19Retrospective cohort studyHydroxychloroquinemedicine.diseaseObesityCOVID-19 Drug TreatmentSurgeryObservational studybusinessJournal of Healthcare Engineering
researchProduct

Reduction of Cardiac Fibrosis by Interference With YAP-Dependent Transactivation

2022

Background: Conversion of cardiac stromal cells into myofibroblasts is typically associated with hypoxia conditions, metabolic insults, and/or inflammation, all of which are predisposing factors to cardiac fibrosis and heart failure. We hypothesized that this conversion could be also mediated by response of these cells to mechanical cues through activation of the Hippo transcriptional pathway. The objective of the present study was to assess the role of cellular/nuclear straining forces acting in myofibroblast differentiation of cardiac stromal cells under the control of YAP (yes-associated protein) transcription factor and to validate this finding using a pharmacological agent that interf…

Transcriptional ActivationPhysiologyfibrosismyofibroblastsVerteporfinheart failureYAP-Signaling ProteinsSettore MED/11 - Malattie dell'Apparato CardiovascolareSettore MED/23 - Chirurgia Cardiacafibrosis; heart failure; myofibroblasts; stromal cell; transcription factorsstromal cellPhosphoproteinscell mechanics; fibrosis; heart failure; myofibroblasts; stromal cell; YAP transcription factor;MiceYAP transcription factorcell mechanicsSettore CHIM/09 - Farmaceutico Tecnologico Applicativotranscription factorsTrans-ActivatorsAnimalsHumansCardiology and Cardiovascular MedicineAdaptor Proteins Signal Transducing
researchProduct